Abu Dhabi: The Abu Dhabi Public Health Centre (ADPHC) and AstraZeneca FZ LLC have entered a strategic partnership to enhance public health initiatives and improve outcomes for chronic obstructive pulmonary disease (COPD) patients in Abu Dhabi. The collaboration was formalized through a Memorandum of Understanding (MoU) signed on May 13, 2025, by Dr. Omniyat Al Hajeri of ADPHC and Sameh El Fangary of AstraZeneca during the 25th IUHPE World Conference on Health Promotion at the Abu Dhabi National Exhibition Centre.
According to Emirates News Agency, the partnership aims to deliver comprehensive solutions that enhance public awareness, promote early screening, and provide advanced care for COPD patients. Dr. Rashed Alsuwaidi, Director General of ADPHC, highlighted the initiative's alignment with the Abu Dhabi Public Health System Sustainability and Resilience (PHSSR) report, emphasizing a healthier Abu Dhabi through proactive and innovative approaches.
Sameh El Fangary of AstraZeneca noted that the collaboration marks a significant step in advancing public health and tackling chronic respiratory diseases in the UAE. The MoU focuses on sharing global best practices, driving education, and enabling early diagnosis and treatment pathways, aiming for improved health outcomes and quality of life for patients.
The agreement outlines a shared vision to enhance population health through coordinated efforts in disease awareness, prevention, and best practice sharing. The two-year partnership is structured around three key pillars: disease awareness, disease prevention, and best practice sharing. Each pillar targets specific aspects of COPD care and management to reduce the disease burden in Abu Dhabi.
A joint task force from ADPHC and AstraZeneca will oversee the project's execution, ensuring strategic alignment and progress tracking. The collaboration will proceed with detailed documentation and mutual approval from both parties' leadership.
ADPHC remains committed to addressing non-communicable diseases through innovative public health systems, while AstraZeneca brings its expertise in managing NCDs, including respiratory diseases like COPD. This partnership underscores the commitment of both entities to improving public health and advancing chronic disease management in Abu Dhabi.